<DOC>
	<DOCNO>NCT02902718</DOCNO>
	<brief_summary>The purpose pilot study evaluate feasibility Mē device home facial skin rejuvenation .</brief_summary>
	<brief_title>MĒ Device At-Home Skin Rejuvenation</brief_title>
	<detailed_description>The mē home use device FDA approve device hair removal skin type body region include face . The device use Elōs technology combination electrical field radio frequency ( RF ) intense optical energy simultaneously apply tissue find synergistic effect . Elōs technology use clinic non-ablative skin rejuvenation . The level Elōs energy use professional device clinic much high level energy use mē device home use . The current study design evaluate safety efficacy mē device home-use non-ablative skin rejuvenation . Healthy female volunteer , seek facial skin rejuvenation treatment enrol . The study include 7 visit clinic . The defined area treatment one facial sub area ( e.g. , forehead , peri-orbital , cheek , peri oral ) . Subjects provide device instruct method usage . The subject perform treatment clinic home accord schedule detail intervention section . Follow ups take place 1 2 month visit . Optional additional follow visit take place 3 6 month initial treatment . Evaluations include skin safety , tolerability procedure , improvement assessment study doctor subject , satisfaction . Optionally , before/after picture follow-up visit v baseline sent blind evaluator .</detailed_description>
	<criteria>1 . Healthy female age 25 60 . 2 . Willing sign Informed consent form photo release form . 3 . Having visible line wrinkle periorbital perioral region face ( Fitzpatrick elastosis degree 36 ) . 4 . Able willing comply visit , treatment evaluation schedule requirement . 5 . Agree make change exist skincare regime , use study product , study period . 6 . If female , must either postmenopausal surgically sterilize , use medically acceptable form birth control least 3 month prior enrollment ( i.e. , oral contraceptive , IUD , contraceptive implant , barrier method spermicide abstinence ) . 1 . Subjects currently use use prior 30 day skin product contain alpha hydroxy acid ( AHA ) e.g . glycolic , lactic , citric , mandelic acid contain product retinol/tretinoin contain product exfoliate wash , mask scrub microdermabrasion skin care product treatment area . 2 . Subjects unwilling maintain daily skin care regimen duration study . 3 . Subjects skin pathology condition could interfere evaluation i.e . personal family history skin cancer , rosacea and/or require use interfere topical systemic therapy . 4 . Subjects synthetic metal implant permanent cosmetic tattoo test area . 5 . Subjects history abnormal scarring , e.g . keloid significant scar area treat . 6 . Subjects bleed disorder take anticoagulation medication , include heavy use aspirin . 7 . Subjects participate clinical investigation involve face within 30 day prior first plan treatment subject plan participate concomitant facial study trial . 8 . Subjects , pregnant , pregnant give birth last 3 month , currently breast feeding , might become pregnant course study . 9 . Subjects history light trigger seizure . 10 . Subjects prior use neurotoxin e.g . Botox® , collagen , fat injection and/ method skin augmentation ( enhancement inject implanted material ) face chemical peel within 6 month initial laser application plan course study . 11 . Subject 's use oral isotretinoin ( Accutane® ) within 12 month initial device application course study . 12 . Subjects facial skin treatment professional laser , light base , radiofrequency device within last year . 13 . Subjects ever facial skin treatment home use laser , light base radiofrequency device , i.e . PaloVia® Tria® . 14 . Subjects facial plastic surgery within last 12 month initial laser application plan course study . 15 . Subjects sun exposure use tan bed 4 week prior start study .</criteria>
	<gender>Female</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>